| |
2004 |
2005 |
| EUR million |
|
|
| Changes in fair values of hedging instruments,
recognized in stockholders’ equity |
64 |
(15) |
| Gains (losses) on hedging instruments,
recognized in the income statement |
4 |
3 |
| Changes in fair values of available-for-sale
securities, recognized in stockholders’ equity |
12 |
9 |
| Gains (losses) on available-for-sale
securities, recognized in the income statement |
(6) |
– |
| Revaluation surplus (IFRS 3) |
66 |
– |
Actuarial gains (losses) on defined benefit
obligations
for pensions and other post-employment benefits |
(740) |
(1,207) |
| Exchange differences on translation of
operations outside the euro zone |
(304) |
857 |
| Deferred taxes on valuation adjustments,
recognized directly in stockholders’ equity |
251 |
470 |
| Deferred taxes on valuation adjustments,
removed from stockholders’ equity
and recognized in the income statement |
(2) |
– |
| Valuation adjustments recognized
directly in stockholders’ equity |
(655) |
117 |
| Income after taxes |
682 |
1,595 |
| Total income and expense recognized
in the financial statements |
27 |
1,712 |
| of which attributable
to minority interest |
(3) |
6 |
| of which attributable
to Bayer AG stockholders |
30 |
1,706 |
top
E-mail this page
Download Acrobat Reader